Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

IMAGIO Imaging and Advanced Guidance for Workflow Optimization in Interventional Oncology

Coordinator
Philips Medical Systems Nederland BV, Netherlands
Runs
1 May 2023 to 31 December 2028
Status
Running
EU funding
€24.3m
Total cost
€37.3m
Partners
36 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101112053

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Lung and liver cancers were among the top three leading causes of cancer death in 2020 with 1.8 million and 830.000 deaths, respectively. On the other hand, soft tissue sarcomas are relatively uncommon cancers diagnosed in about 1% of all adults, but much more common in children and young adults, accounting for 7–10% of paediatric malignancies; they are an important cause of death in the 14–29 years age group.

Interventional Oncology involves miniaturized instruments (biopsy needles, ablation electrodes, intravascular catheters) and minimally-invasive access, guided by imaging techniques (X-ray, ultrasound, computed tomography, magnetic resonance imaging) – to target cancer with ablative or localized drug delivery strategies. Interventional Oncology can be used as a stand-alone approach, or in combination with the other approaches (‘pillars’) to enhance treatment efficacy.

While cancer survival has significantly improved over time through innovations in each individual pillar, our current understanding of cancer now leads us to an intertwining of pillars and multimodal care pathways: Interventional Oncology is uniquely suited to leverage and enhance the effects of the conventional therapy pillars, while reducing the burden on the healthcare system. IMAGIO will leverage Interventional Oncology in the clinical setting to improve the cancer survival outcomes, through minimally invasive, efficient, and affordable care.

We will deliver four complete, multimodal care pathways for two of the most aggressive cancers (liver, lung) and one of the most debilitating when treated with current approaches (sarcoma):1. Multimodal interventional imaging for fast and precise radioembolization therapy of liver cancer; 2. Multimodal ablation therapy of liver cancer; 3. Multimodal diagnosis and therapy in early-stage lung cancer; and 4. Multimodal MR-HIFU-enabled therapy for abdominal sarcoma.

IMAGIO will mature the next-generation interventional imaging across the full spectrum, from pre-clinical developments to impact validation in clinical trials. Expertise on Interventional Oncology and immunotherapy will be leveraged from pioneering clinical research centres and leading industry covering the full value chain of oncological care, as well as cancer patient and professional organisations. Such synergetic partnerships will accelerate the impact of the technologies and transform the way healthcare solutions are delivered, providing access to safe, fast, and effective care.

By focusing on the local delivery of therapy, IMAGIO will drive the substitution of conventional higher dose systemic alternatives or invasive surgical approaches, thereby accelerating recovery, reducing complication rates and the number of patient visits.

Topics

Who is involved

OrganisationCityCountryRole
Philips Medical Systems Nederland BVBestNetherlandsCoordinator
Cancer Patients EuropeBruxelles / BrusselBelgiumParticipant
European Cancer Patient CoalitionBruxelles / BrusselBelgiumParticipant
Janssen Pharmaceutica NVBeerseBelgiumParticipant
Siop EuropeBruxelles / BrusselBelgiumParticipant
Eidgenoessische Technische Hochschule ZuerichZuerichSwitzerlandAssociatedpartner
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Gremse-It GmbHAachenGermanyParticipant
Klinikum Der Universitaet Zu KoelnKoelnGermanyParticipant
Philips GmbHHamburgGermanyParticipant
Profound Medical GmbHHamburgGermanyParticipant
Thermosome GmbHPlaneggGermanyParticipant
Nanovi A/sKongens LyngbyDenmarkParticipant
Profound Medical OyVantaaFinlandParticipant
Varsinais-Suomen HyvinvointialueTurkuFinlandParticipant
Varsinais-Suomen Sairaanhoitopiirin KuntayhtymaTurkuFinlandParticipant
Luxium SolutionsSaint-Pierre-Les-NemoursFranceParticipant
Philips Medical Systems Technologies LtdHaifaIsraelParticipant
Fondazione Irccs Istituto Nazionale Dei TumoriMilanItalyParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Flash Pathology B VAmsterdamNetherlandsParticipant
Nederlandse Leverpatienten Vereniging's-HertogenboschNetherlandsParticipant
Stichting Longkanker NederlandUtrechtNetherlandsParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
Stichting VuAmsterdamNetherlandsParticipant
Technische Universiteit DelftDelftNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Universiteit TwenteEnschedeNetherlandsParticipant
Janssen Cilag LimitedHigh WycombeUnited KingdomThird party
Pfizer R&D UK LimitedSandwichUnited KingdomAssociatedpartner
The Newcastle Upon Tyne Hospitals Nhs Foundation TrustNewcastle-Upon-TyneUnited KingdomAssociatedpartner
Imaginab, IncInglewood CaUnited StatesParticipant
Johnson & Johnson Enterprise Innovation IncNew BrunswickUnited StatesThird party
NeuWave Medical, Inc.MadisonUnited StatesAssociatedpartner
Pfizer IncNew York CityUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI